Researchers identify blockers of CNS effects of PD1 cancer therapy
In mouse models, a group headed by Marco Prinz from University Freiburg demonstrated that adverse side effects of immune cancer therapies with PD1...
AC Immune and Takeda ink US$2.1bn biobucks deal
Under the US$2.1bn biobucks deal, Pharma giant Takeda gets the globally exclusive right to licence AC Immune SA's active immunisation therapy...
Three companies launch gene therapy alliance for eye diseases
Today, the companies officially announced the launch of the GEAR partnership (Evaluation of Adeno-Associated Virus Vector Gene Therapy for the...
Forbion closes first Bioeconomy Fund with US$75m
Life Science investor Forbion opens a new sector for its lead partners who were eager to put money into industries within the ESG standards. At...
British PrecisionLife Ltd inks partnership with Metrodora Institute
The Oxford-based Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) expert PrecisionLife Ltd and US-based clinical specialist...
Unitaid awards Medincell US$6m to fight malaria
The funding commitment for MedinCell Corp’es reformulation of the antipararsitic ivermectin comes after great progress in malaria vaccines: The...
Memo Therapeutics AG increases Series C financing to CHF45m
New investors Ysios Capital and Kurma Partners joined existing Series C round investors including Pureos Bioventures, Swisscanto, Vesalius...